Aligos Therapeutics vs DBV Technologies
DBV Technologies is the larger business, with $5.6m of revenue in fiscal 2025 against $2.2m for Aligos Therapeutics (2.6 times as much). DBV Technologies grew faster (35.8% against -39.5%). Aligos Therapeutics kept more of each dollar of sales as profit: a net margin of -1106.7% against -2607.3%.
| Latest fiscal year | Aligos TherapeuticsALGS, 2025 | DBV TechnologiesDBVT, 2025 |
|---|---|---|
| Revenue | $2.2m | $5.6m |
| Revenue growth | -39.5% | 35.8% |
| Net income | −$24.2m | −$147m |
| Operating margin | — | -2609.2% |
| Net margin | -1106.7% | -2607.3% |
| Return on equity | -196.9% | -149.8% |
| Free cash flow | −$82.5m | −$122m |
| Cash | $18.3m | $194m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | 125 |
| Market value | $28.7m | $4.08bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 7 sales |